Compare RDNT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDNT | GPCR |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.3B |
| IPO Year | 1996 | 2023 |
| Metric | RDNT | GPCR |
|---|---|---|
| Price | $61.78 | $53.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $86.00 | ★ $104.64 |
| AVG Volume (30 Days) | ★ 850.6K | 697.0K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,616,630,000.00 | N/A |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $45.00 | $13.24 |
| 52 Week High | $85.84 | $94.90 |
| Indicator | RDNT | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 26.34 |
| Support Level | $53.23 | $18.36 |
| Resistance Level | $74.55 | $93.91 |
| Average True Range (ATR) | 3.51 | 3.10 |
| MACD | -0.91 | -0.74 |
| Stochastic Oscillator | 19.40 | 7.70 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.